MEI Pharma Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de MEI Pharma.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.3%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	20 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)

Feb 17

Increases to CEO Compensation Might Be Put On Hold For Now at MEI Pharma, Inc. (NASDAQ:MEIP)

Dec 30

Need To Know: Analysts Are Much More Bullish On MEI Pharma, Inc. (NASDAQ:MEIP)

Nov 19

We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash Wisely

May 18

Need To Know: The Consensus Just Cut Its MEI Pharma, Inc. (NASDAQ:MEIP) Estimates For 2022

Mar 26

Newsflash: MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Have Been Trimming Their Revenue Forecasts

Feb 12

MEI Pharma: Another PI3K Delta Progressing To The FDA

Feb 01

Need To Know: Analysts Just Made A Substantial Cut To Their MEI Pharma, Inc. (NASDAQ:MEIP) Estimates

Dec 02

The Independent Non-Executive Director of MEI Pharma, Inc. (NASDAQ:MEIP), Frederick Driscoll, Just Sold 40% Of Their Holding

Feb 25

New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)

Feb 11

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como MEI Pharma no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:MEIP - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2025	N/A	-45	N/A	N/A	1
9/30/2024	N/A	-47	-43	-43	N/A
6/30/2024	65	18	-50	-50	N/A
3/31/2024	67	26	-44	-44	N/A
12/31/2023	73	20	-53	-53	N/A
9/30/2023	105	41	-56	-56	N/A
6/30/2023	49	-32	-53	-52	N/A
3/31/2023	59	-38	-57	-57	N/A
12/31/2022	63	-31	-62	-62	N/A
9/30/2022	42	-54	-56	-56	N/A
6/30/2022	41	-54	-49	-49	N/A
3/31/2022	37	-47	-45	-44	N/A
12/31/2021	35	-64	-43	-43	N/A
9/30/2021	36	-60	-35	-35	N/A
6/30/2021	35	-41	-33	-32	N/A
3/31/2021	52	-53	48	48	N/A
12/31/2020	45	-31	52	54	N/A
9/30/2020	33	-43	42	43	N/A
6/30/2020	28	-47	33	34	N/A
3/31/2020	5	-24	-44	-43	N/A
12/31/2019	5	-38	-44	-44	N/A
9/30/2019	6	-5	-31	-31	N/A
6/30/2019	5	-17	-30	-29	N/A
3/31/2019	4	-39	-25	-25	N/A
12/31/2018	4	-28	-20	-20	N/A
9/30/2018	2	-46	-27	-27	N/A
6/30/2018	2	-40	N/A	-21	N/A
3/31/2018	2	-25	N/A	-21	N/A
12/31/2017	6	-20	N/A	-13	N/A
9/30/2017	22	-2	N/A	-12	N/A
6/30/2017	23	3	N/A	3	N/A
3/31/2017	23	1	N/A	3	N/A
12/31/2016	18	-4	N/A	-3	N/A
9/30/2016	1	-21	N/A	-3	N/A
6/30/2016	N/A	-21	N/A	-18	N/A
3/31/2016	N/A	-21	N/A	-21	N/A
12/31/2015	N/A	-24	N/A	-25	N/A
9/30/2015	N/A	-28	N/A	-27	N/A
6/30/2015	N/A	-33	N/A	-28	N/A
3/31/2015	N/A	-36	N/A	-27	N/A
12/31/2014	N/A	-34	N/A	-24	N/A
9/30/2014	N/A	-31	N/A	-22	N/A
6/30/2014	N/A	-27	N/A	-19	N/A
3/31/2014	N/A	-22	N/A	-16	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de MEIP es superior a la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de MEIP crezcan más rápidamente que el mercado US

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de MEIP crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de MEIP crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de MEIP crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de MEIP se prevé que sea elevada dentro de 3 años.

MEI Pharma Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates increase by 61%

Price target decreased by 12% to US$2.27

Price target decreased to US$2.90

Consensus revenue estimates increase by 26%

Price target increased to US$5.83

Consensus forecasts updated

Recent updates

MEI Pharma, Inc., Annual General Meeting, Jan 30, 2025

MEI Pharma, Inc. Announces Management Changes

MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data

MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

MEI Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $10.3 million.

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023

MEI Pharma, Inc., Annual General Meeting, Dec 18, 2023

MEI Pharma, Inc. Declares Special Cash Dividend of Common Stock, Payable on December 6, 2023

MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023

MEI Pharma, Inc. Announces Board Changes

MEI Pharma, Inc. to Report Fiscal Year 2023 Results on Sep 26, 2023

MEI Pharma, Inc. Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN) in Patients with Previously Treated Metastatic Colorectal Cancer

MEI Pharma, Inc. Announces Chief Financial Officer Changes, Effective as of August 1, 2023

MEI Pharma, Inc. Announces Change of CFO, Effective No Later Than September 1, 2023

MEI Pharma, Inc. Announces Executive Changes

Funicular Fund, LP, managed by Cable Car Capital, LLC, Anson Funds Management LP, Anson Advisors Inc., Anson Management GP LLC, Bruce R. Winson, Amin Nathoo and Moez Kassam submitted a proposal to acquire remaining 85.2% stake in MEI Pharma, Inc. (NasdaqCM:MEIP) for $45.4 million.

Funicular Fund, LP, managed by Cable Car Capital, LLC, Anson Funds Management LP, Anson Advisors Inc., Anson Management GP LLC, Bruce R. Winson, Amin Nathoo and Moez Kassam submitted a proposal to acquire remaining 85.2% stake in MEI Pharma, Inc. (NasdaqCM:MEIP) for $45.4 million.

MEI Pharma, Inc Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)

Consensus revenue estimates increase by 61%

Price target decreased by 12% to US$2.27

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Increases to CEO Compensation Might Be Put On Hold For Now at MEI Pharma, Inc. (NASDAQ:MEIP)

Price target decreased to US$2.90

MEI Pharma, Inc. Initiates Realignment of Its Clinical Development Efforts

Consensus revenue estimates increase by 26%

Kyowa Kirin Co., Ltd. and MEI Pharma, Inc. Announce Topline Data from Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-Cell Non-Hodgkin’s Lymphoma in Japan

Need To Know: Analysts Are Much More Bullish On MEI Pharma, Inc. (NASDAQ:MEIP)

Price target increased to US$5.83

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

MEI Pharma, Inc. Announces Not Stand for Re-Election of Directors

MEI Pharma, Inc., Annual General Meeting, Dec 06, 2022

MEI Pharma, Inc. Announces Not Stand for Re-Election of Cheryl L. Cohen as Member of the Board of Directors

Mei Pharma Announces Changes to Board of Directors

MEI Pharma, Inc. Announces Board Changes

Consensus forecasts updated

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

MEI Pharma, Inc. to Report Fiscal Year 2022 Results on Sep 08, 2022

Price target decreased to US$4.81

MEI Pharma and Kyowa Kirin Announce Publication in the Lancet Oncology of Data from Phase 1B Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-Cell Malignancy

MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

MEI Pharma, Inc. announced delayed 10-Q filing

We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash Wisely

MEI Pharma Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates increase by 11%

Consensus revenue estimates increase by 11%

Need To Know: The Consensus Just Cut Its MEI Pharma, Inc. (NASDAQ:MEIP) Estimates For 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Newsflash: MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Have Been Trimming Their Revenue Forecasts

MEI Pharma, Inc. Announces New Key Executive Appointments

No longer forecast to breakeven

MEI Pharma: Another PI3K Delta Progressing To The FDA

Need To Know: Analysts Just Made A Substantial Cut To Their MEI Pharma, Inc. (NASDAQ:MEIP) Estimates

Consensus revenue estimates fall to US$38.1m

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce Data from Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma

Price target increased to US$10.89

Independent Non Executive Director Kevan Clemens has left the company

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.019 loss in 1Q 2021)

We're Not Very Worried About MEI Pharma's (NASDAQ:MEIP) Cash Burn Rate

Price target increased to US$11.11

Full year 2021 earnings released: US$0.45 loss per share (vs US$0.51 loss in FY 2020)

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce First Patient Dosed in the Phase 3 Coastal Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-Cell Lymphoma

Forecast to breakeven in 2024

MEI Pharma, Inc.(NasdaqCM:MEIP) dropped from Russell 3000E Value Index